17 Matching Annotations
  1. Last 7 days
    1. Functional characterisation of a novel class of in-frame insertion variants of KRAS and HRAS

      [Paper-level Aggregated] PMCID: PMC6547725

      Evidence Type(s): Oncogenic, Functional, Predictive

      Justification: Oncogenic: The text describes several RAS variants, including classical oncogenic mutations in KRAS and NRAS, and indicates that these mutations are associated with increased GTP loading and enhanced RAS signaling. Functional: The evidence discusses the impact of VMOS RAS variants on GTP hydrolysis and their interaction with GEFs and GAPs, suggesting alterations in their functional properties compared to wild type proteins. Predictive: The analysis of the VMOS RAS variants indicates potential changes in signaling capabilities, which could be used to predict the biological behavior of these variants in a clinical context.

      Gene→Variant (gene-first): RASA1(5921):Gln61 KRAS(3845):p.G12A KRAS(3845):p.G13H KRAS(3845):p.Q22K KRAS(3845):p.G12V NRAS(4893):p.Q61L

      Genes: RASA1(5921) KRAS(3845) NRAS(4893)

      Variants: Gln61 p.G12A p.G13H p.Q22K p.G12V p.Q61L

    2. An in-house database search for insertions comparable to the VMOS RAS variants revealed one in-frame insertion in KRAS in a case suspected for Noonan syndrome (Fig. 7A). Furthermore, a screen of the current literature an

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 27

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the impact of the insertions on the catalytic Gln61 might be stronger, indicating an alteration in molecular function related to GTP hydrolysis.

      Gene→Variant (gene-first): 5921:Gln61

      Genes: 5921

      Variants: Gln61

    3. The biophysical characterisation of the VMOS RAS variants showed two opposing effects. VMOS RAS variants appeared insensitive to the action of GEFs with a consequently decrease of signalling capability. On the other hand

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 25

      Evidence Type(s): Functional, Oncogenic

      Justification: Functional: The passage discusses how the HRAS p.G12V variant alters the signaling capability by affecting GTP hydrolysis and inducing phosphorylation of ERK and AKT, indicating a change in molecular function. Oncogenic: The HRAS p.G12V variant is implicated in inducing signaling pathways that are associated with tumor development, as evidenced by the increased levels of phosphorylated ERK and AKT in the transfected cells.

      Gene→Variant (gene-first): 3845:p.G12V

      Genes: 3845

      Variants: p.G12V

    4. To analyse the effect of the VMOS RAS variants on GAP catalysed GTP hydrolysis, G-proteins were incubated in the presence of various concentration of RAS-GAP. GTP and GDP content was analysed after termination of the rea

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 22

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The passage discusses the classical oncogenic variant KRAS p.G12V in the context of its effect on GTP hydrolysis, indicating its role in tumor development or progression. Functional: The passage describes how the variant KRAS p.G12V affects the biochemical function of GTP hydrolysis, demonstrating its impact on molecular activity in the presence of RAS-GAP.

      Gene→Variant (gene-first): 3845:p.G12V

      Genes: 3845

      Variants: p.G12V

    5. GTP hydrolysis was followed over time by terminating the reactions at different points in time, and GDP and GTP contents analysis by HPLC. The intrinsic GTP hydrolysis rates of VMOS RAS variants were reduced by a factor

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 21

      Evidence Type(s): Functional, Oncogenic

      Justification: Functional: The passage discusses how the p.G12V variant alters the intrinsic GTP hydrolysis rates, indicating a change in molecular function related to protein activity. Oncogenic: The p.G12V variant is described as a classical oncogenic variant, suggesting its role in tumor development or progression.

      Gene→Variant (gene-first): 3845:p.G12V

      Genes: 3845

      Variants: p.G12V

    6. The interaction of G-protein and the nucleotide is stabilised in the ternary complex with the effector and in consequence the rate of nucleotide dissociation is reduced. This effect was used to analyse the interaction of

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 18

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: KRAS p.G12V is described as a classical oncogenic variant, indicating its contribution to tumor development or progression. Functional: The passage discusses how KRAS p.G12V alters the intrinsic dissociation rate of mGppNHp compared to wild type, indicating a change in molecular function.

      Gene→Variant (gene-first): 3845:p.G12V

      Genes: 3845

      Variants: p.G12V

    7. The clinical context indicated that VMOS RAS variants cause enhanced RAS signalling, but the outcome of the in silico analysis is not unambiguously supporting this expectation. In fact, it strongly suggested deficiencies

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Functional, Oncogenic

      Justification: Functional: The passage discusses the impact of the p.Q61L variant on nucleotide exchange, effector binding, and GTP hydrolysis, indicating that it alters molecular or biochemical function. Oncogenic: The p.Q61L variant is described as a classic pathogenic missense mutation, suggesting its contribution to tumor development or progression.

      Gene→Variant (gene-first): 4893:p.Q61L

      Genes: 4893

      Variants: p.Q61L

    8. On amino acid level the DNA duplications and insertions found in the VMOS RAS variants resulted in an insertion of mainly duplicated sequence around position 65 (Fig. 2A). It is difficult to predict to what extent the in

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 10

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the insertions around Gln61 likely alter the molecular interactions and functions of the protein, particularly affecting GTP hydrolysis and interactions with GEFs and GAPs.

      Gene→Variant (gene-first): 5921:Gln61

      Genes: 5921

      Variants: Gln61

    9. Sensitive NGS based screening of frequently mutated positions in a panel of multiple genes were applied in 299 cases. In 108 cases, putative causative variants were identified, of which in 15 cases RAS genes were affecte

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 5

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The passage discusses mutations in RAS genes, including p.G12A, p.G13H, and p.Q22K, which are described as classical oncogenic mutations that affect tumor development and progression. Functional: The passage indicates that the p.Q22K mutation is associated with increased GTP loading, suggesting that it alters molecular function related to protein activity.

      Gene→Variant (gene-first): 3845:p.G12A 3845:p.G13H 3845:p.Q22K

      Genes: 3845

      Variants: p.G12A p.G13H p.Q22K

    10. An in-house database search for insertions comparable to the VMOS RAS variants revealed one in-frame insertion in KRAS in a case suspected for Noonan syndrome (Fig. 7A). Furthermore, a screen of the current literature an

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 27

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the impact of the insertions on the catalytic Gln61 might be stronger, indicating an alteration in molecular function related to GTP hydrolysis.

      Gene→Variant (gene-first): 5921:Gln61

      Genes: 5921

      Variants: Gln61

    11. The biophysical characterisation of the VMOS RAS variants showed two opposing effects. VMOS RAS variants appeared insensitive to the action of GEFs with a consequently decrease of signalling capability. On the other hand

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 25

      Evidence Type(s): Functional, Oncogenic

      Justification: Functional: The passage discusses how the HRAS p.G12V variant alters the signaling capability by affecting GTP hydrolysis and inducing phosphorylation of ERK and AKT, indicating a change in molecular function. Oncogenic: The HRAS p.G12V variant is implicated in inducing signaling pathways that are associated with tumor development, as evidenced by the increased levels of phosphorylated ERK and AKT in the transfected cells.

      Gene→Variant (gene-first): 3845:p.G12V

      Genes: 3845

      Variants: p.G12V

    12. To analyse the effect of the VMOS RAS variants on GAP catalysed GTP hydrolysis, G-proteins were incubated in the presence of various concentration of RAS-GAP. GTP and GDP content was analysed after termination of the rea

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 22

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The passage discusses the classical oncogenic variant KRAS p.G12V in the context of its effect on GTP hydrolysis, indicating its role in tumor development or progression. Functional: The passage describes how the variant KRAS p.G12V affects the biochemical function of GTP hydrolysis, demonstrating its impact on molecular activity in the presence of RAS-GAP.

      Gene→Variant (gene-first): 3845:p.G12V

      Genes: 3845

      Variants: p.G12V

    13. GTP hydrolysis was followed over time by terminating the reactions at different points in time, and GDP and GTP contents analysis by HPLC. The intrinsic GTP hydrolysis rates of VMOS RAS variants were reduced by a factor

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 21

      Evidence Type(s): Functional, Oncogenic

      Justification: Functional: The passage discusses how the p.G12V variant alters the intrinsic GTP hydrolysis rates, indicating a change in molecular function related to protein activity. Oncogenic: The p.G12V variant is described as a classical oncogenic variant, suggesting its role in tumor development or progression.

      Gene→Variant (gene-first): 3845:p.G12V

      Genes: 3845

      Variants: p.G12V

    14. The interaction of G-protein and the nucleotide is stabilised in the ternary complex with the effector and in consequence the rate of nucleotide dissociation is reduced. This effect was used to analyse the interaction of

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 18

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: KRAS p.G12V is described as a classical oncogenic variant, indicating its contribution to tumor development or progression. Functional: The passage discusses how KRAS p.G12V alters the intrinsic dissociation rate of mGppNHp compared to wild type, indicating a change in molecular function.

      Gene→Variant (gene-first): 3845:p.G12V

      Genes: 3845

      Variants: p.G12V

    15. The clinical context indicated that VMOS RAS variants cause enhanced RAS signalling, but the outcome of the in silico analysis is not unambiguously supporting this expectation. In fact, it strongly suggested deficiencies

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Functional, Oncogenic

      Justification: Functional: The passage discusses the impact of the p.Q61L variant on nucleotide exchange, effector binding, and GTP hydrolysis, indicating that it alters molecular or biochemical function. Oncogenic: The p.Q61L variant is described as a classic pathogenic missense mutation, suggesting its contribution to tumor development or progression.

      Gene→Variant (gene-first): 4893:p.Q61L

      Genes: 4893

      Variants: p.Q61L

    16. On amino acid level the DNA duplications and insertions found in the VMOS RAS variants resulted in an insertion of mainly duplicated sequence around position 65 (Fig. 2A). It is difficult to predict to what extent the in

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 10

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the insertions around Gln61 likely alter the molecular interactions and functions of the protein, particularly affecting GTP hydrolysis and interactions with GEFs and GAPs.

      Gene→Variant (gene-first): 5921:Gln61

      Genes: 5921

      Variants: Gln61

    17. Sensitive NGS based screening of frequently mutated positions in a panel of multiple genes were applied in 299 cases. In 108 cases, putative causative variants were identified, of which in 15 cases RAS genes were affecte

      [Paragraph-level] PMCID: PMC6547725 Section: RESULTS PassageIndex: 5

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The passage discusses mutations in RAS genes, including p.G12A, p.G13H, and p.Q22K, which are described as classical oncogenic mutations that affect tumor development and progression. Functional: The passage indicates that the p.Q22K mutation is associated with increased GTP loading, suggesting that it alters molecular function related to protein activity.

      Gene→Variant (gene-first): 3845:p.G12A 3845:p.G13H 3845:p.Q22K

      Genes: 3845

      Variants: p.G12A p.G13H p.Q22K